| Domain | Core finding / statistic | Suggested ontology terms | Evidence type | Key source / date / DOI |
|---|---|---|---|---|
| Identifiers / definition | Mowat-Wilson syndrome is a rare congenital neurodevelopmental disorder caused by heterozygous ZEB2 haploinsufficiency; prevalence commonly cited at ~1:50,000–70,000 live births; OMIM disease identifier: **OMIM #235730**; causal gene: **ZEB2** at 2q22.3, **OMIM *605802** (pqac-00000000, pqac-00000005) | MONDO: Mowat-Wilson syndrome; HPO: Intellectual disability, Seizure, Hirschsprung disease, Corpus callosum agenesis | Human clinical + review | Zou et al., 2020, Exp Ther Med, Oct 2020, https://doi.org/10.3892/etm.2020.9393; Birkhoff et al., 2021, Genes, Jul 2021, https://doi.org/10.3390/genes12071037 |
| Inheritance / recurrence | Inheritance is **autosomal dominant**, but most reported cases are **de novo** heterozygous loss-of-function variants; recurrence risk is generally low but not zero because parental germline mosaicism is possible in principle (direct recurrence data limited in retrieved evidence) (pqac-00000000, pqac-00000006) | HPO: De novo mutation; autosomal dominant inheritance | Human clinical + review | Zou et al., 2020, https://doi.org/10.3892/etm.2020.9393; Peter et al., 2024, Feb 2024, https://doi.org/10.3390/ijms25052838 |
| ZEB2 genetics / variant spectrum | >220 pathogenic ZEB2 variants had been identified by 2020; a 2024 review compiled **298 patients** and found **exon 8 accounted for 66% (198/298)** of variants; **>90%** were **nonsense or frameshift**; the recurrent **c.2083C>T** variant represented **11%** of 298 reported patients (pqac-00000000, pqac-00000006, pqac-00000011) | HGNC: ZEB2; Sequence ontology labels: nonsense, frameshift, missense, splice-site, deletion | Human aggregated genetic evidence | Peter et al., 2024, Int J Mol Sci, Feb 2024, https://doi.org/10.3390/ijms25052838; Zou et al., 2020, https://doi.org/10.3892/etm.2020.9393 |
| Functional consequence | Disease mechanism is predominantly **loss of function / haploinsufficiency** of a SMAD-binding transcription factor with roles in transcriptional repression/activation, chromatin regulation, neural crest development, and neurodevelopment (pqac-00000000, pqac-00000010, pqac-00000017) | GO: transcription regulation; neural crest cell migration; TGF-beta/BMP signaling | Human genetic + animal/model mechanistic | Caraffi et al., 2024, Eur J Hum Genet, Feb 2024, https://doi.org/10.1038/s41431-024-01548-4; van de Putte et al., 2007, Jun 2007, https://doi.org/10.1093/hmg/ddm093 |
| Major neurodevelopmental phenotype | Core phenotype includes **moderate-to-severe intellectual disability** with severe speech impairment and delayed motor milestones; mean walking age reported as about **4 years** in aggregate review data (pqac-00000006, pqac-00000012) | HPO: Global developmental delay; Intellectual disability; Delayed walking; Speech delay | Human clinical + review | Peter et al., 2024, https://doi.org/10.3390/ijms25052838; Zou et al., 2020, https://doi.org/10.3892/etm.2020.9393 |
| Epilepsy / EEG | Seizures or abnormal EEG were reported in **84%** in the 2024 aggregate review; epilepsy occurred in **3/4** patients in one 2020 case series, with variable course including spontaneous remission in one child (pqac-00000006, pqac-00000012) | HPO: Seizure; Abnormal EEG | Human clinical + review | Peter et al., 2024, https://doi.org/10.3390/ijms25052838; Zou et al., 2020, https://doi.org/10.3892/etm.2020.9393 |
| Gastrointestinal / enteric phenotype | **Hirschsprung disease affects ~50%** of patients in aggregate estimates; chronic constipation is also common, including patients without proven aganglionosis (pqac-00000006, pqac-00000012, pqac-00000019) | HPO: Hirschsprung disease; Constipation | Human clinical + review | Peter et al., 2024, https://doi.org/10.3390/ijms25052838; Birkhoff et al., 2021, https://doi.org/10.3390/genes12071037 |
| Cardiac phenotype | Congenital heart disease was reported in **58%** in the 2024 review, supporting routine cardiology assessment (pqac-00000006) | HPO: Congenital heart defect | Human aggregated clinical evidence | Peter et al., 2024, Int J Mol Sci, Feb 2024, https://doi.org/10.3390/ijms25052838 |
| Brain / growth / dysmorphism | Frequently reported features include **microcephaly**, corpus callosum and hippocampal anomalies, ventriculomegaly/white matter changes, and distinctive facial gestalt; brain malformations were estimated at about **80%** in review data (pqac-00000013, pqac-00000019) | HPO: Microcephaly; Corpus callosum agenesis; Ventriculomegaly; Hypertelorism; Uplifted earlobe | Human clinical + review | Peter et al., 2024, https://doi.org/10.3390/ijms25052838; Birkhoff et al., 2021, https://doi.org/10.3390/genes12071037 |
| 2024 DNA methylation episignature | A 2024 study analyzed **29** molecularly confirmed cases (discovery **n=24**, validation **n=5**) and identified a **296-probe** episignature; **98.6%** of differentially methylated probes were **hypomethylated**; classifier scores separated all MWS cases from controls and **56 other neurodevelopmental disorder episignatures** (pqac-00000008, pqac-00000009, pqac-00000010) | DNA methylation signature; EpiSign; ZEB2 locus | Human molecular biomarker | Caraffi et al., 2024, Eur J Hum Genet, Feb 2024, https://doi.org/10.1038/s41431-024-01548-4 |
| Diagnostic implications | Diagnosis is primarily established by **molecular testing of ZEB2** using single-gene sequencing, multigene neurodevelopmental panels, exome/genome sequencing, and deletion/duplication analysis; the 2024 episignature provides an additional diagnostic biomarker, especially for uncertain/atypical cases (pqac-00000004, pqac-00000008, pqac-00000009) | HPO-based phenotyping; DNA methylation signature; sequence analysis; copy-number analysis | Human diagnostic evidence | Zou et al., 2020, https://doi.org/10.3892/etm.2020.9393; Caraffi et al., 2024, https://doi.org/10.1038/s41431-024-01548-4 |
| Management / real-world care | No disease-modifying therapy was identified in retrieved evidence; current care is **supportive and multidisciplinary**, including seizure management, surgery for Hirschsprung disease and congenital anomalies, feeding/nutrition support, developmental therapies, and surveillance for cardiac/GI/GU/neurologic issues (pqac-00000001, pqac-00000018) | MAXO labels: antiseizure medication therapy; surgical correction; gastrostomy feeding support; speech therapy; physical therapy; occupational therapy | Human clinical practice / supportive care | Peter et al., 2024, https://doi.org/10.3390/ijms25052838; Cordelli et al., 2021, Jun 2021, https://doi.org/10.3390/genes12070982 |
| Current study implementation | Retrieved registry evidence showed one disease-specific study: **NCT07476417**, an observational oral-health/dentofacial/OHRQoL study, **not yet recruiting**, planned enrollment **25** | Oral health; quality of life | Observational study registry | ClinicalTrials.gov record NCT07476417 |
| Modifier / variable expressivity | Variable penetrance of Hirschsprung disease suggests modifiers beyond ZEB2. A 2026 preprint proposed a **RET enhancer risk haplotype** as a modifier of HSCR penetrance in MWS; this is promising but **not yet peer-reviewed** (pqac-00000002, pqac-00000003) | RET enhancer haplotype; variable expressivity | Human genomic preprint | Collins et al., medRxiv, Mar 2026, https://doi.org/10.64898/2026.03.19.26348831 |
| Molecular pathways | ZEB2 participates in **TGF-beta/BMP-SMAD** signaling and also modulates **Wnt, Notch, and FGF** pathway components; it can recruit **p300/KAT2B** for activation and CtBP/HDAC-associated repressive machinery for repression (pqac-00000010, pqac-00000018, pqac-00000020) | GO: TGF-beta receptor signaling pathway; BMP signaling; Wnt signaling; Notch signaling; neurogenesis | Review + mechanistic synthesis | Caraffi et al., 2024, https://doi.org/10.1038/s41431-024-01548-4; Cordelli et al., 2021, https://doi.org/10.3390/genes12070982; Birkhoff et al., 2021, https://doi.org/10.3390/genes12071037 |
| Cell / tissue systems affected | Major affected systems include **central nervous system**, **enteric nervous system**, **craniofacial neural crest derivatives**, **heart**, and **urogenital tract** (pqac-00000000, pqac-00000017, pqac-00000018) | UBERON: brain, heart, intestine; CL: neural crest cell, cortical neuron, GABAergic interneuron, Bergmann glial cell | Human + animal | Zou et al., 2020, https://doi.org/10.3892/etm.2020.9393; van de Putte et al., 2007, https://doi.org/10.1093/hmg/ddm093; Cordelli et al., 2021, https://doi.org/10.3390/genes12070982 |
| Model systems | Useful models include **neural crest-specific conditional mouse knockout**, **cortical conditional knockouts**, **heterozygous Zeb2 mutant mice**, **zebrafish knockdown/perturbation models**, and emerging **patient-derived iPSC systems**; no single model captures the full human phenotype (pqac-00000007, pqac-00000014, pqac-00000015, pqac-00000017, pqac-00000019) | Mouse model; zebrafish model; iPSC model | Animal + in vitro | van de Putte et al., 2007, https://doi.org/10.1093/hmg/ddm093; Epifanova et al., 2019, Feb 2019, https://doi.org/10.1016/j.brainres.2018.09.034; Birkhoff et al., 2021, https://doi.org/10.3390/genes12071037 |
| Key mechanistic model findings | Neural crest-specific Zfhx1b/Zeb2 loss causes craniofacial, GI, cardiac, melanocyte, and autonomic defects; cortical models show altered neuro-/gliogenesis timing via **Ntf3**, **Sfrp1/Wnt**, and **Fgf9**-linked mechanisms; interneuron defects support altered **GABAergic** development and seizure susceptibility (pqac-00000014, pqac-00000016, pqac-00000017, pqac-00000018) | GO: neural crest cell migration; forebrain development; GABAergic neuron differentiation; gliogenesis | Animal mechanistic | Epifanova et al., 2019, https://doi.org/10.1016/j.brainres.2018.09.034; van de Putte et al., 2007, https://doi.org/10.1093/hmg/ddm093; Cordelli et al., 2021, https://doi.org/10.3390/genes12070982 |


*Table: This compact table summarizes high-yield disease knowledge-base facts for Mowat-Wilson syndrome, including identifiers, ZEB2 genetics, major phenotype frequencies, 2024 episignature data, diagnostics, management, and model systems. It is designed to support rapid curation with evidence type labeling and source-linked citations.*